Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly reports positive data from gastric cancer drug trial

Lilly reports positive data from gastric cancer drug trial

7th October 2013

Lilly has announced the publication of positive findings from Regard, a phase III clinical trial of the investigational gastric cancer therapy ramucirumab.

Data featured in The Lancet showed that the drug helped to improve survival rates when used as a single agent in patients with advanced gastric cancer who have experienced disease progression after initial chemotherapy.

This was the first phase III study with either a single-agent biologic or an anti-angiogenic therapy to show improved overall survival and progression-free survival in advanced gastric cancer patients.

Ramucirumab has also demonstrated its safety and efficacy in a second phase III trial called Rainbow, positive findings from which were announced last month.

Dr Richard Gaynor, vice-president for product development and medical affairs for Lilly Oncology, said: "We are pleased with this data of ramucirumab as a single agent in advanced gastric cancer, a devastating disease where the prognosis for patients is poor."

Lilly is hoping to launch a number of innovative new therapies in the coming months as part of its wider growth strategy, thus helping to offset the recent impact of patent expiries on key products.ADNFCR-8000103-ID-801646309-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.